Sentiment-Signal
13,0
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (16.03.2026)
HOCH Abgang Schlüsselpersonen (16.03.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 16.03.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | tion 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoi |
| 04.09.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | tion 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoi |
| 13.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | tion 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Principal Officers; Election of Directors; App |
Stammdaten
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Unternehmen & Branche
| Name | VERACYTE, INC. |
|---|---|
| Ticker | VCYT |
| CIK | 0001384101 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 8071 · Services-Medical Laboratories |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 2,67 Mrd. USD |
| Beta | 1,96 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 517,145,000 | 66,353,000 | 0.82 | 1,406,019,000 | 1,309,576,000 |
| 2025-09-30 | 10-Q | 131,872,000 | 19,137,000 | 0.24 | 1,367,787,000 | 1,257,667,000 |
| 2025-06-30 | 10-Q | 130,164,000 | -980,000 | -0.01 | 1,344,104,000 | 1,221,057,000 |
| 2025-03-31 | 10-Q | 114,473,000 | 7,047,000 | 0.09 | 1,315,411,000 | 1,194,936,000 |
| 2024-12-31 | 10-K | 445,764,000 | 24,138,000 | 0.31 | 1,300,035,000 | 1,175,966,000 |
| 2024-09-30 | 10-Q | 115,860,000 | 15,155,000 | 0.19 | 1,275,021,000 | 1,176,042,000 |
| 2024-06-30 | 10-Q | 114,428,000 | 5,734,000 | 0.07 | 1,234,327,000 | 1,132,523,000 |
| 2024-03-31 | 10-Q | 96,844,000 | -1,864,000 | -0.02 | 1,200,073,000 | 1,118,649,000 |
| 2023-12-31 | 10-K | 361,051,000 | -74,404,000 | -1.02 | 1,114,906,000 | 1,044,102,000 |
| 2023-09-30 | 10-Q | 90,108,000 | -29,618,000 | -0.41 | 1,124,943,000 | 1,054,059,000 |
| 2023-06-30 | 10-Q | 90,322,000 | -8,402,000 | -0.12 | 1,161,114,000 | 1,082,718,000 |
| 2023-03-31 | 10-Q | 82,422,000 | -8,091,000 | -0.11 | 1,157,119,000 | 1,081,259,000 |
| 2022-12-31 | 10-K | 296,536,000 | -36,560,000 | -0.51 | 1,156,422,000 | 1,075,200,000 |
| 2022-09-30 | 10-Q | 75,592,000 | -8,723,000 | -0.12 | 1,125,957,000 | 1,048,177,000 |
| 2022-06-30 | 10-Q | 72,864,000 | -9,532,000 | -0.13 | 1,144,198,000 | 1,064,151,000 |
| 2022-03-31 | 10-Q | 67,783,000 | -14,461,000 | -0.20 | 1,173,589,000 | 1,085,190,000 |
| 2021-12-31 | 10-K | 219,514,000 | -75,563,000 | -1.11 | 1,187,825,000 | 1,096,514,000 |
| 2021-09-30 | 10-Q | 60,370,000 | -14,129,000 | -0.20 | 1,186,356,000 | 1,107,080,000 |
| 2021-06-30 | 10-Q | 55,105,000 | -9,038,000 | -0.13 | 1,027,435,000 | 971,177,000 |
| 2021-03-31 | 10-Q | 36,703,000 | -41,868,000 | -0.66 | 1,025,136,000 | 974,231,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | Leite John | Officer, Chief Commercial Officer-CLIA | Open Market Sale | -5,260 | 35.19 | -185,082.57 | -72,5% | |
| 2026-03-04 | Stapley Marc | Director, Officer, Chief Executive Officer | Open Market Sale | -19,244 | 35.56 | -684,226.19 | -268,0% | |
| 2026-03-04 | Stapley Marc | Director, Officer, Chief Executive Officer | Open Market Sale | -26,279 | 36.28 | -953,367.96 | -373,4% | |
| 2026-03-04 | Chambers Rebecca | Officer, Chief Financial Officer | Open Market Sale | -13,941 | 36.33 | -506,459.80 | -198,4% | |
| 2026-03-04 | Chambers Rebecca | Officer, Chief Financial Officer | Open Market Sale | -4,400 | 35.55 | -156,409.44 | -61,3% | |
| 2026-03-04 | McGuire Annie | Officer, SVP, General Counsel | Open Market Sale | -4,994 | 35.29 | -176,256.24 | -69,0% | |
| 2026-03-04 | McGuire Annie | Officer, SVP, General Counsel | Open Market Sale | -1,664 | 36.34 | -60,468.60 | -23,7% | |
| 2026-03-02 | Febbo Phillip G. | Officer, Chief Scientific & Med Officer | Open Market Sale | -13,425 | 36.16 | -485,429.21 | -190,1% | |
| 2025-12-16 | McGuire Annie | Officer, SVP, General Counsel | Open Market Sale | -10,639 | 43.13 | -458,835.60 | -179,7% | |
| 2025-12-16 | McGuire Annie | Officer, SVP, General Counsel | Open Market Sale | -100 | 43.68 | -4,368.00 | -1,7% | |
| 2025-12-05 | EASTHAM KARIN | Director | Open Market Sale | -12,808 | 45.84 | -587,080.30 | -229,9% | |
| 2025-12-05 | EASTHAM KARIN | Director | Open Market Sale | -6,392 | 44.52 | -284,571.20 | -111,5% | |
| 2025-12-05 | EASTHAM KARIN | Director | Open Market Sale | -800 | 46.59 | -37,271.84 | -14,6% | |
| 2025-12-04 | McGuire Annie | Officer, SVP, General Counsel | Open Market Sale | -702 | 47.51 | -33,352.02 | -13,1% | |
| 2025-12-04 | Chambers Rebecca | Officer, Chief Financial Officer | Open Market Sale | -8,537 | 46.61 | -397,946.28 | -155,9% | |
| 2025-12-04 | Chambers Rebecca | Officer, Chief Financial Officer | Open Market Sale | -4,741 | 47.25 | -224,008.93 | -87,7% | |
| 2025-12-04 | Stapley Marc | Director, Officer, Chief Executive Officer | Open Market Sale | -4,448 | 46.90 | -208,613.42 | -81,7% | |
| 2025-12-04 | Stapley Marc | Director, Officer, Chief Executive Officer | Open Market Sale | -3,220 | 47.35 | -152,462.17 | -59,7% | |
| 2025-12-04 | Leite John | Officer, Chief Commercial Officer-CLIA | Open Market Sale | -1,278 | 47.51 | -60,717.78 | -23,8% | |
| 2025-12-04 | McGuire Annie | Officer, SVP, General Counsel | Open Market Sale | -720 | 47.10 | -33,908.76 | -13,3% | |
| 2025-11-25 | JONES EVAN/ FA | Director | Open Market Sale | -1,106 | 50.25 | -55,575.73 | -21,8% | |
| 2025-11-25 | Leite John | Officer, Chief Commercial Officer-CLIA | Open Market Sale | -2,808 | 50.00 | -140,400.00 | -55,0% | |
| 2025-11-20 | Holstein Jens | Director | Open Market Sale | -7,049 | 42.48 | -299,416.85 | -117,3% | |
| 2025-11-20 | Holstein Jens | Director | Open Market Sale | -1,460 | 43.21 | -63,085.87 | -24,7% | |
| 2025-11-20 | Holstein Jens | Director | Open Market Sale | -1,491 | 40.95 | -61,060.33 | -23,9% | |
| 2025-11-10 | Wygant Jonathan | Officer, VP, Chief Accounting Officer | Open Market Sale | -5,102 | 42.33 | -215,978.37 | -84,6% | |
| 2025-11-07 | Wygant Jonathan | Officer, VP, Chief Accounting Officer | Open Market Sale | -5,818 | 40.21 | -233,928.98 | -91,6% | |
| 2025-11-05 | JONES EVAN/ FA | Director | Open Market Sale | -24,296 | 45.73 | -1,110,990.48 | -435,2% | |
| 2025-11-05 | JONES EVAN/ FA | Director | Open Market Sale | -10,837 | 43.80 | -474,701.78 | -185,9% | |
| 2025-11-05 | JONES EVAN/ FA | Director | Open Market Sale | -5,872 | 45.07 | -264,640.47 | -103,7% | |
| 2025-11-05 | JONES EVAN/ FA | Director | Open Market Sale | -1,126 | 43.03 | -48,455.05 | -19,0% | |
| 2025-11-05 | JONES EVAN/ FA | Director | Open Market Sale | -657 | 46.38 | -30,468.77 | -11,9% | |
| 2025-11-05 | JONES EVAN/ FA | Director | Open Market Sale | -408 | 41.74 | -17,031.18 | -6,7% | |
| 2025-11-05 | McGuire Annie | Officer, SVP, General Counsel | Open Market Sale | -6,466 | 40.00 | -258,640.00 | -101,3% | |
| 2025-11-05 | EASTHAM KARIN | Director | Open Market Sale | -9,674 | 40.02 | -387,191.21 | -151,7% | |
| 2025-11-05 | Chambers Rebecca | Officer, Chief Financial Officer | Open Market Sale | -7,000 | 41.00 | -287,000.00 | -112,4% | |
| 2025-10-06 | Febbo Phillip G. | Officer, Chief Scientific & Med Officer | Open Market Sale | -8,349 | 36.02 | -300,709.27 | -117,8% | |
| 2025-10-01 | McGuire Annie | Officer, SVP, General Counsel | Open Market Sale | -2,160 | 35.00 | -75,607.56 | -29,6% | |
| 2025-10-01 | EPSTEIN ROBERT S | Director | Open Market Sale | -21,473 | 35.08 | -753,204.13 | -295,0% | |
| 2025-10-01 | Leite John | Officer, Chief Commercial Officer-CLIA | Open Market Sale | -2,539 | 35.00 | -88,865.00 | -34,8% | |
| 2025-09-19 | McGuire Annie | Officer, SVP, General Counsel | Open Market Sale | -2,283 | 33.69 | -76,919.52 | -30,1% | |
| 2025-09-04 | Stapley Marc | Director, Officer, Chief Executive Officer | Open Market Sale | -7,667 | 30.41 | -233,132.77 | -91,3% | |
| 2025-06-13 | EASTHAM KARIN | Director | Open Market Sale | -4,590 | 26.66 | -122,387.76 | -47,9% | |
| 2025-06-13 | Bhanji Muna | Director | Open Market Sale | -4,589 | 26.67 | -122,366.60 | -47,9% | |
| 2025-06-04 | Leite John | Officer, Chief Commercial Officer-CLIA | Open Market Sale | -2,809 | 27.20 | -76,409.86 | -29,9% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.